BioCentury
ARTICLE | Clinical News

BIOD-531: Phase IIa started

November 16, 2015 8:00 AM UTC

Biodel began the Phase IIa Study 3-157 to compare BIOD-531 alone or in combination with Victoza liraglutide vs. Humalog insulin lispro plus Lantus insulin glargine in 14 Type II diabetics. Patients will receive 4 treatments: BIOD-531 with breakfast, lunch and dinner; BIOD-531 with breakfast and dinner; BIOD-531 with Victoza at breakfast and dinner; and Humalog at breakfast, lunch and dinner with Lantus. ...